1. A method of reducing the interindividual variability of platelet reaction and metabolic load in humans in the treatment and / or prevention of thrombosis and / or embolism observed after administration of an antiplatelet agent such as clopidogrel, ticlopidine, comprising administering to a person in need of a composition comprising an effective amount of S-oxo-clopidogrel or its derivatives according to the formula IIA Formula IIA or a pharmaceutically acceptable salt, where R represents hydrogen or hydrolyzable groups v.2. The method of claim 1, wherein the method further comprises administering one or more antiplatelet agents selected from the group consisting of aspirin, cilostazol and dipyridamole. The method of claim 1, wherein the interindividual variability is due to CYP450 polymorphism, or the inability to efficiently metabolize clopidogrel. The method according to claim 3, where the given CYP450 polymorphism is CYP2C19 * 2 or CYP2C19 * 17.5. The method according to claim 1, where this interindividual variability is due to the efflux transport of P-glycoprotein. The method according to claim 1, where the specified method allows to avoid or reduce side effects associated with the metabolite of clopidogrel acid according to the formula IV of Formula IV7. The method according to claim 1, where the method allows to achieve a therapeutic effect, higher or equivalent to that observed after administration of a significantly higher dose of clopidogrel. The method according to claim 1, where the specified method results in the formation in vivo of an active metabolite of clopidogrel in a concentration higher than or equivalent to a concentration of1. Способ уменьшения межиндивидуальной вариабельности тромбоцитарной реакции и метаболической нагрузки у человека при лечении и/или профилактике тромбообразования и/или эмболии, наблюдаемой после введения антитромбоцитарного средства, такого как клопидогрель, тиклопидин, включающий в себя введение, нуждающемуся в этом че
